Personalised cancer vaccine cuts melanoma return risk by 42%

A personalised cancer vaccine given with a widely used immunotherapy drug cut the risk of patients dying or their melanoma returning by 42% in a major trial. It also reduced the risk of the skin cancer spreading by 38% over two years. Makers MSD and Moderna are testing the approach on kidney, bladder and lung cancers, though experts want longer studies.